Molecular Partners (NASDAQ:MOLN) Posts Quarterly Earnings Results, Beats Estimates By $0.11 EPS

Molecular Partners (NASDAQ:MOLN) announced its earnings results on Thursday. The company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.11, Zacks reports. Molecular Partners had a negative return on equity of 39.31% and a negative net margin of 1,043.01%.

Molecular Partners Stock Performance

NASDAQ:MOLN opened at $4.90 on Friday. The company has a 50-day moving average price of $5.11 and a 200-day moving average price of $5.39. The stock has a market cap of $197.78 million, a price-to-earnings ratio of -2.28 and a beta of 1.06. Molecular Partners has a 12 month low of $3.32 and a 12 month high of $12.70.

Molecular Partners Company Profile

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.